Ralf Liebhold / Shutterstock.com

16 April 2024NewsBiotechnologyMarisa Woutersen

Moderna COVID-19 vaccine dispute halted by court

A US District Court has granted a motion to stay the company’s lawsuit against Pfizer and BioNTech | Decision pauses proceedings until two inter partes review proceedings are resolved.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Court sides with Arbutus on claims in Moderna COVID vaccine patent row

9 April 2024 Delaware district court more convinced by Arbutus on claim construction points | Canadian biotech “pleased” with outcome in latest round of dispute over lipid nanoparticles delivery system.

PTAB grants BioNTech and Pfizer's inter partes review against Moderna

21 March 2024 US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.

More on this story

Biotechnology

Court sides with Arbutus on claims in Moderna COVID vaccine patent row

9 April 2024 Delaware district court more convinced by Arbutus on claim construction points | Canadian biotech “pleased” with outcome in latest round of dispute over lipid nanoparticles delivery system.

PTAB grants BioNTech and Pfizer's inter partes review against Moderna

21 March 2024 US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.

More on this story

Biotechnology

Court sides with Arbutus on claims in Moderna COVID vaccine patent row

9 April 2024 Delaware district court more convinced by Arbutus on claim construction points | Canadian biotech “pleased” with outcome in latest round of dispute over lipid nanoparticles delivery system.

PTAB grants BioNTech and Pfizer's inter partes review against Moderna

21 March 2024 US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent